iShares MSCI Indonesia ETF vs 22nd Century Group Inc — how do they compare? iShares MSCI Indonesia ETF trades at $12.23, while 22nd Century Group Inc trades at $4.27 (market cap $1.52M). Which is the better fit depends on your goals.
| EIDO | XXII | |
|---|---|---|
52-Week High | $19.22 | $1.47K |
52-Week Low | $10.80 | $3.90 |
Market Cap | — | $1.52M |
Sector | — | Technology |
Enterprise Value | — | -$6.71M |
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Indonesia ETF (EIDO) trades at $12.20, up 1.08% on the day, while technical indicators signal a bearish trend with moving averages and overall signals in sell territory. Recent news highlights Indonesia's economic initiatives, including a $15 billion AI-integrated free-meal program and central bank rate hikes to support the rupiah, which directly impacts this country-focused ETF. The fund's dividend was reported to have dropped 27% in 2025, raising questions about underlying asset performance.
The outlook for EIDO is tied to Indonesia's macroeconomic stability and government policy execution. Investment opportunity lies in exposure to Indonesia's growth initiatives, but risks include currency volatility from Bank Indonesia's defensive actions, geopolitical pressures on emerging markets, and the ETF's high-yield but potentially unstable dividend profile.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →